It is the broad, long-term goal of this program to build on and extend the current knowledge in the field of bone marrow transplantafion and hematological malignancies. This program is a mulfidisciplinary clinical, basic and translational research effort whose overall goal is to improve outcomes for patients with solid and liquid malignancies. To this end, the investigators of this application will ufilize the approach of translational research, bridging the novel experimental concepts and observations made at the laboratory bench to clinical applicafion at the pafients'bedsides. In both basic and clinical areas, the HCTHM Program fosters interacfions between many Programs and members of the DCCI. The Program includes 35 members from 11 basic and clinical departments within Duke University. Total funding for program members is $68,881,117, of which $64,009,143 is from peer- reviewed sources. A cancer focus is illustrated by $976,102 or 1.5% of funding from the NCI, the American Cancer Society or the Department of Defense. From 2004- 2008, program members published 706 papers in peer-reviewed journals cited in PubMed. Of these publicafions, 6.4% are the result of intra-programmatic collaborations and 13% due to inter-programmafic collaborations.
The aims of the Program are: 1. To optimize the use of allogeneic and autologous transplantation of hematopoiefic stem cells. 2. To use and compare various alternative sources of hematopoietic stem cells for allogeneic transplantation. 3. To develop novel preparatory regimens for allogeneic stem cell transplantation. 4. To understand the basic biology of graft versus tumor (GvT) and to explore new ways to induce GvT effects following transplantation. 5. To study the nature of and define the problems associated with hematopoiefic and immunologic reconstitution after allogeneic transplantation with the overall goal of developing novel supportive care measures for patients transplanted with stem cells from alternative and mismatched donors. 6. To understand hematopoietic stem cell development and control of differentiation. 7. To promote effective interactions of the members of the Duke Comprehensive Cancer Institute that will stimulate new translational research efforts to improve the care of patients with hematologic malignancies. 8. To identify new cellular and stromal targets for therapy with antibodies or small molecules, leading to evaluafion of various labeling techniques, such as using radiolabels or diphtheria toxins, of small molecules and antibodies with subsequent clinical evaluation of safety and efficacy. 9. To evaluate the importance of different signaling mechanisms in leukemogenesis or lymphomagenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-40
Application #
8601820
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
40
Fiscal Year
2014
Total Cost
$29,310
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications